Israel · Delayed Price · Currency is ILS · Price in ILA Bio-View Statistics
Total Valuation
Bio-View has a market cap or net worth of ILS 10.80 million. The enterprise value is 5.73 million.
| Market Cap | 10.80M |
| Enterprise Value | 5.73M |
Important Dates
The next estimated earnings date is Monday, November 30, 2026.
| Earnings Date | Nov 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Bio-View has 13.40 million shares outstanding. The number of shares has increased by 5.34% in one year.
| Current Share Class | 13.40M |
| Shares Outstanding | 13.40M |
| Shares Change (YoY) | +5.34% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 50.18% |
| Owned by Institutions (%) | 14.06% |
| Float | 6.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.52 |
| PB Ratio | 1.61 |
| P/TBV Ratio | 1.61 |
| P/FCF Ratio | 21.91 |
| P/OCF Ratio | 20.85 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.28 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 11.63 |
Financial Position
The company has a current ratio of 1.62, with a Debt / Equity ratio of 0.46.
| Current Ratio | 1.62 |
| Quick Ratio | 1.05 |
| Debt / Equity | 0.46 |
| Debt / EBITDA | n/a |
| Debt / FCF | 6.29 |
| Interest Coverage | -24.11 |
Financial Efficiency
Return on equity (ROE) is -98.38% and return on invested capital (ROIC) is -301.21%.
| Return on Equity (ROE) | -98.38% |
| Return on Assets (ROA) | -13.29% |
| Return on Invested Capital (ROIC) | -301.21% |
| Return on Capital Employed (ROCE) | -56.07% |
| Weighted Average Cost of Capital (WACC) | 4.35% |
| Revenue Per Employee | 690,000 |
| Profits Per Employee | -436,933 |
| Employee Count | 31 |
| Asset Turnover | 0.89 |
| Inventory Turnover | 1.70 |
Taxes
In the past 12 months, Bio-View has paid 6.87 million in taxes.
| Income Tax | 6.87M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -58.88% in the last 52 weeks. The beta is -0.03, so Bio-View's price volatility has been lower than the market average.
| Beta (5Y) | -0.03 |
| 52-Week Price Change | -58.88% |
| 50-Day Moving Average | 87.25 |
| 200-Day Moving Average | 137.66 |
| Relative Strength Index (RSI) | 31.04 |
| Average Volume (20 Days) | 7,356 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bio-View had revenue of ILS 20.70 million and -13.11 million in losses. Loss per share was -0.94.
| Revenue | 20.70M |
| Gross Profit | 10.20M |
| Operating Income | -4.97M |
| Pretax Income | -6.24M |
| Net Income | -13.11M |
| EBITDA | -4.67M |
| EBIT | -4.97M |
| Loss Per Share | -0.94 |
Balance Sheet
The company has 8.17 million in cash and 3.10 million in debt, with a net cash position of 5.07 million or 0.38 per share.
| Cash & Cash Equivalents | 8.17M |
| Total Debt | 3.10M |
| Net Cash | 5.07M |
| Net Cash Per Share | 0.38 |
| Equity (Book Value) | 6.72M |
| Book Value Per Share | 0.48 |
| Working Capital | 5.99M |
Cash Flow
In the last 12 months, operating cash flow was 518,000 and capital expenditures -25,000, giving a free cash flow of 493,000.
| Operating Cash Flow | 518,000 |
| Capital Expenditures | -25,000 |
| Depreciation & Amortization | 293,000 |
| Net Borrowing | -550,000 |
| Free Cash Flow | 493,000 |
| FCF Per Share | 0.04 |
Margins
Gross margin is 49.29%, with operating and profit margins of -24.00% and -63.32%.
| Gross Margin | 49.29% |
| Operating Margin | -24.00% |
| Pretax Margin | -30.16% |
| Profit Margin | -63.32% |
| EBITDA Margin | -22.58% |
| EBIT Margin | -24.00% |
| FCF Margin | 2.38% |
Dividends & Yields
Bio-View does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.34% |
| Shareholder Yield | -5.34% |
| Earnings Yield | -121.36% |
| FCF Yield | 4.56% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 1, 2026. It was a reverse split with a ratio of 0.1.
| Last Split Date | Jun 1, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Bio-View has an Altman Z-Score of -1.58 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.58 |
| Piotroski F-Score | 4 |